However, in the treatment of certain types of tumors, such as BRCA1/2-mutated and HER2-positive BC, the efficacy of talazoparib, a potent PARP1/2 inhibitor, did not surpass conventional chemotherapy [147]. This evidence concerns the gene BRCA1 and breast cancer.